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Background: Noonan syndrome (NS) is an autosomal dominant genetic condition that has a num-
ber of clinical features, including bleeding diathesis and a number of hematological abnormalities 
including clotting factor deficiencies, von Willebrand disease and abnormal platelet count/function. 
Methods: We evaluated the frequency/types of bleeding disorders, and associated hematological 
laboratory findings, in patients with NS, using published data from 1965  to 2014.  
Results: Of 45 studies identified, 31 included data for 428 patients with NS. Of these patients, 
43% had reported bleeding, 26% had no reported bleeding and no bleed data was reported for 
31%. Most patients (90%) had bleeding-related laboratory test abnormalities, but only 194 (45%) 
had a confirmed diagnosis of a specific bleeding disorder. Abnormal laboratory tests included: 
prolonged prothrombin time, activated partial thromboplastin time, and other platelet-related 
disorders. Of the 194 patients with a confirmed diagnosis of a specific bleeding disorder, 153 
(79%) had single clotting factor deficiencies, von Willebrand disease or platelet-related disorders, 
and 41 (21%) had multiple deficiencies including platelet-related disorders. 
Conclusion: As patients with NS can experience multiple bleeding disorders, including abnor-
mal platelet function, clinical evaluations should be performed at diagnosis, after diagnosis, 
before any surgery is undertaken, and if patients become symptomatic.
Keywords: bleeding disorders, children, laboratory test abnormalities, Noonan syndrome, 
screening, surgical procedures
Introduction
Noonan syndrome (NS) is an autosomal dominant genetic condition that affects one 
in 1,000–2,500 individuals. Typical signs of NS include characteristic facial features, 
short stature, congenital heart defect, skeletal and thoracic anomalies, developmental 
delay, and bleeding problems; these are seen in 30%–72% of patients with the condi-
tion.1 Until recently, the molecular etiology of NS was unknown; this, coupled with 
the highly variable phenotype observed in these patients, made diagnosis difficult. It 
is now recognized, however, that ~50% of patients with NS demonstrate pathological 
variants of the PTPN11 gene. This results in the development of NS, or another dis-
order involving PTPN11 (such as LEOPARD syndrome), where cardiac defects also 
frequently manifest as pulmonary valve stenosis and hypertrophic cardiomyopathy.2 
A number of genes are known to play a role in NS; molecular testing of the four best-
recognized genes in NS is now generally available and has identified mutations in 
PTPN11 in ~50%, KRAS in <5%, SOS1 in ~15%, and RAF1 in 3%–17% of patients 
with the disorder.3
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NS can be associated with an increased risk of bleed-
ing and bruising, and a variety of bleeding abnormalities, 
with factor XI deficiency and platelet abnormalities being 
described most frequently.4–6 However, it is not clear whether 
there is any direct correlation between bleeding risk and 
results of coagulation tests so there is currently increased 
focus on evaluating bleeding risk in patients with NS. As 
a consequence of their condition, many patients undergo 
multiple surgeries, often starting in early childhood, so it 
is important to establish bleeding risk prior to any inter-
vention. For example, pulmonary valve stenosis, which is 
often reported in patients with NS, is typically unsuitable 
for interventional balloon dilation due to bleeding risk, and 
usually requires surgery for correction. Also, the presence 
of a partial atrioventricular canal with outflow obstruction 
can result in a demanding surgical procedure to correct the 
malformation.7 The aim of this systematic review was to 
identify the frequency and types of bleeding disorders, and 
to evaluate any links with associated laboratory findings, in 
patients with NS, with a view to providing physicians with 
guidelines on how to evaluate bleeding complications in 
patients with NS.
Methods and results
Publications from 1965 to 2014 were reviewed. They included 
trials, case reports/series, and reviews identified via MED-
LINE®, EMBASE®, and Scopus®. Key search terms included: 
Noonan; bleed*3; hemorrhag*3; thrombocytop*enia; 
h*emostatic; h*emostasis; bleed* diathesis; platelet* 
disorder*.
Studies of patients with NS were included in the analy-
sis only if the bleeding phenotype was described. Studies 
were excluded if NS was not present or not confirmed in 
all cases; the publication was a secondary analysis (review 
of other case reports with no new information); there was 
no patient-level bleeding phenotype information reported 
for any patients. All available patient data were abstracted, 
and included demographics, bleeding symptoms, labora-
tory abnormalities, bleeding score, and specific disorders 
reported. The numbers of patients in each study are shown 
in Table S1.
Of 45 studies identified,1,4–6,8–48 314–6,8–35 had relevant 
data from 428 patients with NS (Figure 1). Of the 31 stud-
ies included, 13 were single case studies, five included <10 
patients, and 13 included >10 patients. The largest cumula-
tive study, including 151 patients,18 had previously been 
reported with 725 and 3133 patients; however, different sets 
of information are presented in each publication. Nearly 
half (49%) of the patients were male; 43% (183 patients) 
had reported bleeding, 26% (112 patients) had not reported 
bleeding, and for 31% (133 patients) there was no data on 
bleeding. Most patients (384; 90%) had some reported labo-
ratory test abnormalities (platelet function and/or coagula-
tion abnormalities). Of the patients with reported bleeding, 
abnormal laboratory tests included: prolonged prothrombin 
time (PT) (29 patients; 7%); activated partial thromboplastin 
time (aPTT) (71 patients; 17%); PT/aPTT (23 patients; 5%); 
and platelet-related disorders (42 patients; 10%). There were 
also reports of normal PT (104 patients; 24%) and aPTT 
(157 patients; 37%).
Figure 1 Prisma figure of studies for inclusion.
Note: *Key search terms included: Noonan; bleed*3; hemorrhag*3; thrombocytop*enia; h*emostatic; h*emostasis; bleed* diathesis; platelet* disorder*.
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In one of the studies of 39 patients (and 28 controls), 
nearly 40% of patients with NS had a bleeding diathesis but 
>90% had platelet function and/or coagulation abnormali-
ties.9 Another study of 13 patients suggested that bleeding 
signs do not appear to be due to coagulation disorders.22
Of the 428 patients evaluated, only 46% (195 patients) had a 
specific diagnosis of factor deficiency, von Willebrand disease, 
or platelet-related disorder. Of these patients, 154 (78%) had 
single-factor deficiencies or von Willebrand disease, and 42 
(22%) had multiple factor deficiencies (Table 1). Of the factor 
deficiencies, factor XI (FXI) deficiency was most common (81 
patients), followed by factor XII (FXII) (34 patients), and factor 
VIII (FVIII) (28 patients) (Table 2). Platelet-related disorders 
were reported in 46 patients, with thrombocytopenia and plate-
let aggregation abnormality being most commonly reported. 
In the 42 patients reporting multiple factor deficiencies, FXI+ 
FXII combined (11 patients), and FVIII+ FXI combined (seven 
patients) were the most common (Table 2).
Table 1 Factor deficiencies and other bleeding disorders reported in patients with NS
Type of deficiency Single factor deficiency Multiple factor deficiency Total
FI 2 1 3
FII 0 1 1
FV 0 5 5
FVII 6 6 12
FVIII 18 12 30
FIX 4 7 11
FX 0 5 5
FXI 57 30 87
FXII 19 16 35
FXIII 1 0 1
vWD 4 6 10
Platelet-relateda 42 5 47
Totalb 153 42 195
Notes: aThrombocytopenia: 20 (two were transient after birth); ITP + cyclooxygenase deficiency: 1; Bernard–Soulier syndrome: 1; platelet aggregation abnormality: 19; 
platelet storage pool deficiency: 1. bTotal is the number of patients with factor deficiencies, and for multiple factor deficiencies patients could have more than one deficiency 
type.
Abbreviations: ITP, idiopathic thrombocytopenia; FI, factor I; FII, factor II; FV, factor V; FVII, factor VII; FVIII, factor VIII; FIX, factor IX; FX, factor X; FXI, factor XI, FXII, 
factor XII; FXIII, factor XIII; NS, Noonan syndrome; vWD, von Willebrand disease.
Table 2 Multiple factor deficiencies and platelet-related disorders reported in patients with NS
Multiple factor deficiency Number of patients
FI + FXI + FXII 1
FII + FXI 1
FV + FVII + FX 1
FV + FVIII 3
FV + FIX + FX 1
FVII + FIX + FXI + vWD 2
FVII + FX 2
FVII + FXII + platelet-related disorder 1
FVIII + FXI + FXII 1
FVIII + vWD 1
FVIII + FXI 7
FIX + FX 1
FIX + FXII + platelet-related disorder 1
FIX + FXI 2
FXI + FXII 11
FXI + vWD 2
FXI + platelet-related disorder 3
FXII + vWD 1
Total 42
Notes: aPlatelet-related disorders included: thrombocytopenia; idiopathic thrombocytopenic purpura + cyclooxygenase deficiency; Bernard–Soulier syndrome, platelet 
aggregation abnormality; platelet storage pool deficiency.
Abbreviations: FI, factor I; FII, factor II; FV, factor V; FVII, factor VII; FVIII, factor VIII; FIX, factor IX; FX, factor X; FXI, factor XI, FXII, factor XII; FXIII, factor XIII; NS, 
Noonan syndrome; vWD, von Willebrand disease.
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Discussion
Physicians are diagnosing NS more readily; however, this 
literature review identifies a clear gap in the evaluation 
and diagnosis of bleeding diathesis and specific bleeding 
disorders in these patients. Indeed, several studies have 
highlighted that there is no correlation between coagulation 
study results and bleeding risk. In one study of 39 patients 
(and 28 controls), whilst only 40% of patients with NS had 
a bleeding diathesis, more than 90% had platelet function 
and/or coagulation abnormalities.9 Another study of 13 
patients suggested that bleeding signs do not appear to be 
due to coagulation disorders.22 These findings suggest that 
screening needs to include tests beyond PT, aPTT and platelet 
count. Therefore, guidelines for clinical evaluation in NS 
should highlight the importance of comprehensive testing, 
as well as the need for specialist involvement by a pediatric 
hematologist in differential diagnosis, both at diagnosis of 
NS and pre-operatively, whenever screening test abnormali-
ties are identified.49
Although there is currently no consensus on the optimum 
strategy for diagnosis of bleeding in patients with NS, a 
review by Roberts et al in 2013 suggested that at diagnosis 
of NS a complete blood cell count (CBC) with differential 
and PT/aPTT should be undertaken. After diagnosis, repeat 
CBC with differential and PT/aPTT if aged 6–12 months at 
initial screen, and pre-operatively, CBC with differential and 
PT/aPTT, then in consultation with hematologist FIX, FXI 
and FXII concentrations, von Willebrand factor, and platelet 
aggregation. Furthermore, if symptomatic, PT/aPTT if bleed-
ing is abnormal or persistent, then refer to a hematologist.50
Due to the inconsistent reporting of platelet test results 
and platelet disorders in the studies included in this analysis, it 
does not appear that appropriate tests are being undertaken in 
clinical practice. Platelet aggregation, for example, needs to be 
conducted on a fresh specimen and is more likely to be offered at 
regional centers. It is therefore important to distinguish between 
abnormalities in platelet function suspected by screening tests 
(eg, platelet function analysis-100) and confirmed platelet func-
tion disorders based upon aggregometry patterns and confirmed 
with flow cytometry, electron microscopy, or genetic testing.
The surprisingly high incidence of multiple coagulation 
disorders suggests that work up in patients with NS needs 
to be more comprehensive. While FXI deficiency was most 
common individually and in combination, there were several 
multiple defects (both factor deficiencies and platelet function 
disorders) reported in the same patient.
Given that several germline mutations including PTPN11 
and SOS1 are reported in patients with NS, there may be a 
possible correlation with bleeding phenotype. However, of the 
studies included in our analysis, only a few evaluated genetic 
mutations in relation to the reported bleeding disorder and 
results were not consistent. An evaluation of patients with NS 
reported PTPN11 gene mutations in 21 of 27 patients, and 
hematological disorders in nine of 27, with authors suggesting 
a near significant correlation.12 Another study of 19 patients 
with NS showed that coagulation abnormalities were reported 
in patients with PTPN11, SOS1 and SOS1/RAF1 mutations 
and without a gene mutation, but they were not correlated with 
a specific gene mutation.14 In addition, a study of 13 patients 
with NS (six with PTPN11 mutations) found that 12/13 had 
normal hematological assessment and only one had a platelet 
function disorder (storage pool disease).22 One of the stud-
ies of 15 patients (14 with PTPN11 mutation and one with 
SOS1 mutation), showed that nine had a bleeding diathesis 
and complained of easy bruising, despite having normal 
platelet count, basic coagulation parameters, fibrinogen and 
antithrombin, and without a relevant reduction of coagulation 
factor activities. Furthermore, three of them had potentially 
acquired von Willebrand disease, which the authors suggested 
may explain the bleeding in those with pulmonary stenosis.47 
Further analysis of a large cohort of individuals with NS has 
suggested that PTPN11 gene mutations are more likely to be 
found in those with pulmonary stenosis, whereas hypertrophic 
cardiomyopathy is less prevalent among those with PTPN11 
mutations.2 Thus, bleeding disorders in NS do not appear to 
correlate with a particular genotype.
There are limitations to this analysis, which included 
mostly spontaneous case reports/series, because the report-
ing of symptoms, laboratory evaluations, and diagnosis may 
have been incomplete. Furthermore, while attempts were 
made to remove duplicate reporting of the same case in both 
an individual case report and prior compiled series/review, 
there may have been cases that were not explicitly referenced. 
When limited coagulation evaluation does not confirm to one 
or more specific diagnoses, it underscores the importance of 
referral to a pediatric hematologist so that the patient’s parents 
can give a detailed bleeding history. This should then be fol-
lowed through with a differential diagnosis, using appropriate 
laboratory assays. In future case reports/series, there is an 
important need to ensure that symptoms, laboratory results, 
and ultimate diagnoses are tracked.
Conclusion
Patients with NS can experience multiple bleeding disorders, 
including platelet-related disorders. Comprehensive clinical 
evaluations should be carried out both at diagnosis, after 
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diagnosis if patients are symptomatic, and prior to any surgi-
cal procedures, even if tests are normal, the risk for bleeding 
events should be carefully considered. Furthermore, as there 
is no current consensus on management of bleeding compli-
cations in patients with NS, it is important that physicians 
closely monitor these patients.
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